Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Veru Inc (NQ: VERU )

0.7307 -0.0101 (-1.36%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veru Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Recap: Veru Q1 Earnings
  Veru (NASDAQ:VERU) reported its Q1 earnings results on Wednesday, February 9, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For February 9, 2022
Companies Reporting Before The Bell • Equinor (NYSE:EQNR) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion. 
Via Benzinga
5 Biotech Stocks to Buy to Benefit From Biden’s New Cancer Cabinet
Joe Biden is redoubling his efforts to fight cancer with a new "cancer cabinet." Here are the biotech stocks to buy that can benefit. 
Via InvestorPlace
Veru's Cancer Candidate Sabizabulin Gets FDA Fast Track Tag For COVID-19
The FDA has granted Fast Track designation to Veru Inc's (NASDAQ: 
Via Benzinga
Promising Developments in Breast Cancer Treatments Ahead in 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against... 
Via FinancialNewsMedia
Veru Posts Mixed Q4 Results
Veru Inc (NASDAQ: VERU) reported fourth-quarter FY21 sales growth of 32.8% year-on-year, to $15.65 million, missing the analyst consensus of $18.17 million. FC2... 
Via Benzinga
Veru: Q4 Earnings Insights
Veru (NASDAQ:VERU) reported its Q4 earnings results on Thursday, December 2, 2021 at 06:30 AM. Here's what investors need to know about the announcement. Earnings Veru... 
Via Benzinga
Veru: Q3 Earnings Insights
Shares of Veru (NASDAQ:VERU) rose 13.2% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 40.00% over the past year to... 
Via Benzinga
48 Biggest Movers From Yesterday
Gainers Splash Beverage Group, Inc. (NYSE: SBEV) shares jumped 70.6% to close at $1.80 on Tuesday after the company announced it received authorization to sell its TapouT... 
Via Benzinga
9 Consumer Staples Stocks Moving In Tuesday's Intraday Session
Gainers Veru (NASDAQ:VERU) shares moved upwards by 21.5% to $6.49 during Tuesday's regular session. As of 12:31 EST, this security is trading at a volume of 7.0... 
Via Benzinga
30 Stocks Moving In Tuesday's Mid-Day Session
Gainers TSR, Inc. (NASDAQ: TSRI) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year.... 
Via Benzinga
Earnings Outlook For Veru
On Thursday, August 12, Veru (NASDAQ:VERU) will report its last quarter's earnings. Here is Benzinga's preview of the company's release. What Are Earnings, Net Income, And... 
Via Benzinga
Why Jim Cramer Likes Grab Holdings
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Veru Inc. (NASDAQ: 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
How Good Are Veru's Earnings? | Return On Capital Employed
According to Benzinga Pro data, during Q4, Veru (NASDAQ:VERU) posted sales of $15.65 million. Earnings were up 34.84%, but Veru still reported an overall loss of $1.87 million. In... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Moderna, Pfizer-BioNTech Ink New Vaccine Deals With UK, GSK-Vir Antibody Show Activity Against Omicron, Chemomab Gets Clearance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus U.K. Signs Deal to Buy Incremental COVID-19 Vaccines From Moderna And Pfizer-... 
Via Benzinga
Exposures COVID-19
Earnings Scheduled For December 2, 2021
Companies Reporting Before The Bell • EHang Holdings (NASDAQ:EH) is expected to report earnings for its third quarter. • LightInTheBox Holding (NYSE:LITB) is... 
Via Benzinga
Earnings Outlook For Veru
Veru (NASDAQ:VERU) is set to give its latest quarterly earnings report on Thursday, 2021-12-02. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
10 Consumer Staples Stocks Moving In Monday's After-Market Session
Gainers 111 (NASDAQ:YI) shares rose 3.81% to $4.35 during Monday's after-market session. The market value of their outstanding shares is at $360.4 million. The company's, Q3... 
Via Benzinga
Cramer Gives His Take On Change Healthcare, Veru And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Change Healthcare Inc. (NASDAQ: CHNG) is a good, steady firm. Cramer said with Veru Inc. (NASDAQ: VERU)... 
Via Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
Exposures Product Safety
Why Veru Stock Vaulted Higher Today
An analyst raised his price target for the stock. 
Via The Motley Fool
Why Veru Stock Blasted Higher on Friday
An analyst argues that the company has far more value than many realize. 
Via The Motley Fool
Veru Stock Gains After Q3 Result Tops Estimates
Veru Inc (NASDAQ: VERU) reported third-quarter FY21 sales growth of 71% year-on-year, to $17.66 million, beating the analyst consensus of $14.10 million. FC2... 
Via Benzinga
Veru's Enobosarm Efficacy Correlates with Androgen Receptor Levels in Metastatic Breast Cancer Patients
Veru Inc (NASDAQ: VERU) has announced additional clinical results from the Phase 2 study evaluating enobosarm, a selective androgen receptor (AR) targeting agent,... 
Via Benzinga
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS... 
Via Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.